{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T14:08:25Z","timestamp":1765807705819,"version":"3.40.5"},"reference-count":32,"publisher":"Wiley","issue":"9","license":[{"start":{"date-parts":[[2019,7,23]],"date-time":"2019-07-23T00:00:00Z","timestamp":1563840000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Pharmacoepidemiology and Drug"],"published-print":{"date-parts":[[2019,9]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Purpose<\/jats:title><jats:p>We evaluated the cardiovascular risk associated with dipeptidyl peptidase\u20104 inhibitors (DPP\u20104Is) as monotherapy compared with other antidiabetic drugs in Japan.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We conducted a nationwide cohort study involving 2\u00a0716\u00a0000 diabetes patients in Japan. New users of any antidiabetic drug as monotherapy between 1 April 2010 and 31 October 2014 were identified. Occurrences of myocardial infarction (MI), heart failure (HF), and stroke requiring hospitalization associated with DPP\u20104Is were compared with those associated with biguanides (BGs), sulfonylureas (SUs), or \u03b1\u2010glucosidase inhibitors (\u03b1\u2010GIs). Adjusted hazard ratios (aHRs) for these outcomes were estimated by Cox proportional hazards model. Propensity score standardization was used to control for confounding.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>We identified 1\u00a0105\u00a0103 patients using DPP\u20104Is, 278\u00a0280 patients using BGs, 273\u00a0449 patients using SUs, and 217\u00a0026 patients using \u03b1\u2010GIs. The risks of MI and HF for DPP\u20104I users were significantly higher than those for BG users (MI: aHR, 1.48 [95%CI, 1.20\u20101.82], HF: aHR, 1.46 [95%CI, 1.31\u20101.62]), while significantly lower than those for SU users (MI: aHR, 0.84 [95%CI, 0.72\u20100.98], HF: aHR, 0.86 [95%CI, 0.81\u20100.92]). The risk of MI for DPP\u20104I users was similar to that for \u03b1\u2010GI users, while the risk of HF for DPP\u20104I users was slightly higher than for \u03b1\u2010GI users (MI: aHR, 0.98 [95%CI, 0.82\u20101.17], HF: aHR, 1.12[95%CI, 1.04\u20101.21]).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Risk of MI and HF requiring hospitalization associated with DPP\u20104Is as monotherapy was significantly higher than BGs, significantly lower than SUs, and similar to \u03b1\u2010GIs.<\/jats:p><\/jats:sec>","DOI":"10.1002\/pds.4847","type":"journal-article","created":{"date-parts":[[2019,7,24]],"date-time":"2019-07-24T05:48:16Z","timestamp":1563947296000},"page":"1166-1174","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Cardiovascular risks associated with dipeptidyl peptidase\u20104 inhibitors monotherapy compared with other antidiabetes drugs in the Japanese population: A nationwide cohort study"],"prefix":"10.1002","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8390-0922","authenticated-orcid":false,"given":"Maki","family":"Komamine","sequence":"first","affiliation":[{"name":"Office of Medical Informatics and Epidemiology Pharmaceuticals and Medical Devices Agency  Tokyo Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0570-2792","authenticated-orcid":false,"given":"Kazuhiro","family":"Kajiyama","sequence":"additional","affiliation":[{"name":"Office of Medical Informatics and Epidemiology Pharmaceuticals and Medical Devices Agency  Tokyo Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1302-9430","authenticated-orcid":false,"given":"Chieko","family":"Ishiguro","sequence":"additional","affiliation":[{"name":"Office of Medical Informatics and Epidemiology Pharmaceuticals and Medical Devices Agency  Tokyo Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0430-9887","authenticated-orcid":false,"given":"Yoshiaki","family":"Uyama","sequence":"additional","affiliation":[{"name":"Office of Medical Informatics and Epidemiology Pharmaceuticals and Medical Devices Agency  Tokyo Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2019,7,23]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1463-1326.2010.01306.x"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.2169\/internalmedicine.56.7428"},{"key":"e_1_2_8_4_1","unstructured":"Evidence\u2010based Practice Guideline for the Treatment of Diabetes in Japan 2013. Nankodo Co Ltd2013."},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.287.19.2570"},{"issue":"4","key":"e_1_2_8_6_1","first-page":"616","article-title":"Cardiovascular safety profile of currently available diabetic drugs","volume":"14","author":"Azimova K","year":"2014","journal-title":"Ochsner J"},{"key":"e_1_2_8_7_1","unstructured":"U.S. Food and Drug Administration.Guidance for industry diabetes mellitus\u2014evaluating cardiovascular risk in new antidiabetic therapies to treat type 2 Diabetes.2008; Available athttps:\/\/www.fda.gov\/downloads\/Drugs\/GuidanceComplianceRegulatoryInformation\/Guidances\/UCM071627.pdf. Accessed 27 April 2018."},{"key":"e_1_2_8_8_1","unstructured":"European Medicibea Agency.Guideline on clinical investigation of medicinal products in the treatment or prevention of diabetes mellitus.2012; Available athttp:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Scientific_guideline\/2012\/06\/WC500129256.pdf. Accessed 27 April 2018."},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1463-1326.2010.01215.x"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1305889"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12093"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1501352"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12000"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1307684"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.7326\/M15-2568"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-016-0350-4"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-018-0737-5"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000007213"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(13)70107-4"},{"key":"e_1_2_8_20_1","unstructured":"Ministry of Health Labour and Welfare.Current Status of Electronic Submission of Health Care Claims and Advancement of Reimbursement of Health Care Service Fee.2015; Available athttp:\/\/www.mhlw.go.jp\/file\/06\u2010Seisakujouhou\u201012400000\u2010Hokenkyoku\/0000099002.pdf. Accessed 27 April 2018."},{"key":"e_1_2_8_21_1","unstructured":"KubotaK AndoT OobaN et al.Validation study of the claims\u2010based definition of acute myocardial infarction: a study in a single university hospital in Japan. 33rd International Conference on Pharmacoepidemiology & Therapeutic Risk Management;2017;Montreal."},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1093\/biomet\/70.1.41"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2005.07.004"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1111\/joim.12197"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc15-0764"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehr077"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12197"},{"key":"e_1_2_8_28_1","doi-asserted-by":"publisher","DOI":"10.4070\/kcj.2017.0324"},{"key":"e_1_2_8_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0195-668X(03)00468-8"},{"key":"e_1_2_8_30_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1463-1326.2010.01349.x"},{"key":"e_1_2_8_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejheart.2008.05.013"},{"key":"e_1_2_8_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejheart.2008.01.014"},{"key":"e_1_2_8_33_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCOUTCOMES.109.908517"}],"container-title":["Pharmacoepidemiology and Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/pds.4847","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/pds.4847","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/pds.4847","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,9]],"date-time":"2023-09-09T03:14:03Z","timestamp":1694229243000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/pds.4847"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7,23]]},"references-count":32,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2019,9]]}},"alternative-id":["10.1002\/pds.4847"],"URL":"https:\/\/doi.org\/10.1002\/pds.4847","archive":["Portico"],"relation":{},"ISSN":["1053-8569","1099-1557"],"issn-type":[{"type":"print","value":"1053-8569"},{"type":"electronic","value":"1099-1557"}],"subject":[],"published":{"date-parts":[[2019,7,23]]},"assertion":[{"value":"2018-04-27","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-06-02","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-07-23","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}